Sign In
Buy CVAC
$4.66
+0 (+0%)
At Close: Apr 02, 2026
CureVac sues Moderna for patent infringement over COVID-19 vaccines
04:52pm, Friday, 24'th Apr 2026
German biotech company CureVac sued Moderna in Delaware federal court on Friday, alleging that Moderna's COVID-19 vaccine Spikevax infringed CureVac patents related to messenger RNA (mRNA) techn
CureVac N.V. (NASDAQ:CVAC) Given Consensus Recommendation of “Hold” by Analysts
05:24am, Sunday, 11'th Jan 2026
CureVac N.V. (NASDAQ: CVAC - Get Free Report) has earned a consensus rating of "Hold" from the six ratings firms that are covering the company, Marketbeat reports. One research analyst has rated the s
BioNTech Achieves Minimum Condition in CureVac Exchange Offer
09:01am, Wednesday, 03'rd Dec 2025
The minimum condition for the offer has been satisfied, with 184,071,410 shares of CureVac, representing approximately 81.74% of CureVac's issued and outstanding shares, tendered prior to the expirati
CureVac N.V. (CVAC) Shareholder/Analyst Call Prepared Remarks Transcript
03:33am, Friday, 28'th Nov 2025
CureVac N.V. ( CVAC ) Shareholder/Analyst Call November 25, 2025 8:00 AM EST Company Participants Mehdi Shahidi Marco Rau Thaminda Ramanayake - Chief Business Officer & Member of Executive Board Alexa
CureVac Announces Voting Results of Extraordinary General Meeting
07:05pm, Tuesday, 25'th Nov 2025
TÜBINGEN, DE AND BOSTON, MA / ACCESS Newswire / November 25, 2025 / CureVac N.V. (Nasdaq:CVAC)(CureVac or the Company), a pioneering multinational biotech company developing a new class of transforma
Brokerages Set CureVac N.V. (NASDAQ:CVAC) PT at $6.83
03:29am, Tuesday, 25'th Nov 2025
CureVac N.V. (NASDAQ: CVAC - Get Free Report) has received a consensus rating of "Hold" from the six brokerages that are covering the stock, Marketbeat Ratings reports. Five research analysts have rat
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates
07:30am, Monday, 24'th Nov 2025
German Federal Cartel Office clearance obtained for the planned BioNTech - CureVac transaction announced on June 12, 2025, marking an important step toward the expected closing later this year Offer p
CureVac: The Hidden Value Of The mRNA Wallet
05:26am, Wednesday, 01'st Oct 2025
CureVac is a pioneering biotech company focused on mRNA drugs for oncology and vaccines. In biotech, value derives from research quality, patent strength, and clinical success probability, not current
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates
07:50am, Friday, 15'th Aug 2025
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates Entered into a definitive Purchase Agreement pursuant to which BioNTech intends to acqui
GSK secures $370 million settlement and future royalties in CureVac mRNA patent dispute
02:51am, Friday, 08'th Aug 2025
GSK PLC (LSE:GSK, NYSE:GSK) will receive an upfront payment of $370 million from CureVac, following a patent settlement involving BioNTech and Pfizer over messenger ribonucleic acid (mRNA) vaccine te
CureVac settles patent dispute litigation with Pfizer and BioNTech
09:00pm, Thursday, 07'th Aug 2025
CureVac said on Thursday that the company and GSK have entered an agreement to a resolve patent dispute with Pfizer and BioNTech related to mRNA-based COVID-19 vaccines.
CureVac Announces Voting Results of General Meeting
04:35pm, Tuesday, 24'th Jun 2025
TÜBINGEN, GERMANY AND BOSTON, MA / ACCESS Newswire / June 24, 2025 / CureVac N.V. (NASDAQ:CVAC), a pioneering multinational biotech company developing a new class of transformative medicines based on
CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech
12:56pm, Friday, 20'th Jun 2025
CVAC jumps 41% in a month after signing a $1.25B deal to be acquired by BioNTech to accelerate mRNA therapy development.
$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of CureVac N.V. (NASDAQ: CVAC)
09:24am, Friday, 20'th Jun 2025
NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVAC, KNW, SOAR, HLGN on Behalf of Shareholders
01:19pm, Friday, 13'th Jun 2025
NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breac
